Veterinary IV Solutions Market Revenue Expected to Hit $2.3 Billion by 2030 at 7.7% CAGR
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Much Is The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?
The veterinary intravenous (iv) solutions market has experienced significant growth in recent years. This market is projected to expand from $1.62 billion in 2025 to $1.75 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.1%. The historical expansion of the market can be attributed to various factors including the increasing incidence of dehydration and electrolyte imbalances in animals, the rising population of companion animals, a growing number of veterinary hospitals and clinics, the widespread adoption of conventional iv solutions, and ongoing technological advancements in veterinary fluid therapy.
The veterinary intravenous (iv) solutions market is projected to experience substantial expansion over the upcoming years. Its valuation is anticipated to reach $2.36 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.7%. This projected growth during the forecast period is fueled by several factors, including an increasing need for sophisticated isotonic and colloid solutions, the rising integration of parenteral nutrition in veterinary practices, the creation of specialized iv solutions tailored for critical care, heightened understanding of the advantages of fluid therapy, and the broadening of veterinary emergency and critical care provisions. Key developments expected during this period involve the creation of advanced isotonic and balanced electrolyte solutions, an increased application of both synthetic and natural colloids, the expansion of parenteral nutrition solutions for both companion and production animals, the uptake of pre-mixed and ready-to-use iv solutions, and the further development of veterinary critical care and emergency fluid therapy.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20686&type=smp
What Drivers Are Influencing The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market?
The growing occurrence of diverse animal diseases is anticipated to drive the expansion of the veterinary intravenous (IV) solutions market in the future. Animal diseases are defined as conditions or health issues that compromise the well-being and functionality of animals, with common examples including anthrax, leptospirosis, rabies, canine distemper, and heartworm disease, among others. This rise in disease prevalence is attributed to multiple factors, such as intensive farming methods, the increasing intrusion of wildlife into human habitats, and the emergence of antibiotic resistance. Veterinary IV solutions are crucial for restoring hydration in animals suffering from illnesses that cause dehydration, like gastroenteritis or severe infections, thereby guaranteeing proper hydration and promoting better overall health. For example, the World Organisation for Animal Health (WOAH), a France-based intergovernmental animal health body, reported in May 2025 that avian influenza outbreaks in mammals more than doubled last year compared to 2023, with 1,022 reported outbreaks in 55 countries against 459 in 2023, highlighting a notable increase in disease prevalence across various species. Consequently, the expanding prevalence of numerous animal diseases is fueling the development of the veterinary intravenous (IV) solutions market.
What Major Segment Divisions Exist Within The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market?
The veterinary intravenous (iv) solutions market covered in this report is segmented –
1) By Product: Isotonic Crystalloids, Dextrose Solutions, Synthetic Colloids, Natural Colloids, Parenteral Nutrition
2) By Animal Type: Companion Animals, Production Animals
3) By End-User: Veterinary Hospitals And Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Isotonic Crystalloids: Normal Saline (0.9% NaCl), Lactated Ringer’s Solution, Dextrose In Water (D5W), Ringer’s Solution, Balanced Electrolyte Solutions
2) By Dextrose Solutions: Dextrose 5% In Water (D5W), Dextrose 10% In Water (D10W), Dextrose 20% In Water (D20W), Dextrose 50% In Water (D50W)
3) By Synthetic Colloids: Hydroxyethyl Starch (HES), Dextran, Gelatins
4) By Natural Colloids: Albumin, Fresh Frozen Plasma (FFP), Blood Products
5) By Parenteral Nutrition: Total Parenteral Nutrition (TPN) Solutions, Partial Parenteral Nutrition Solutions, Lipid Emulsions, Amino Acid Solutions
How Are Trends Shaping The Direction Of The Veterinary Intravenous (IV) Solutions Market?
Leading companies operating in the veterinary intravenous (IV) solutions market are concentrating on creating sophisticated offerings, like fluoroquinolone, to enhance their effectiveness and safety. Fluoroquinolones represent a potent category of antibiotics utilized in both human and animal healthcare for addressing diverse bacterial infections, requiring careful management to lessen the chances of resistance development and adverse reactions. As an illustration, during April 2024, Elanco, a pharmaceutical company based in the US, unveiled Pradalex, an injectable solution containing pradofloxacin, which received approval from the US Food and Drug Administration (FDA), a US health organization. This approval targets swine for treating swine respiratory disease (SRD) linked to bordetella bronchiseptica, Glaesserella (Haemophilus) parasuis, Pasteurella multocida, streptococcus suis, and mycoplasma hyopneumoniae. Pradalex is identified as a 3rd generation fluoroquinolone, classified as a critically important antimicrobial. The product’s labeling specifies that its application is advised only subsequent to evaluating alternative non-fluoroquinolone treatment possibilities.
Which Companies Are Leading Innovation In The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market?
Major companies operating in the veterinary intravenous (iv) solutions market are Merck & Co. Inc., Baxter International Inc., Zoetis Inc., Fresenius Kabi AG, Elanco Animal Health Incorporated, B. Braun Melsungen AG, Virbac SA, Dechra Pharmaceuticals PLC, Vetoquinol SA, Norbrook Laboratories Limited, Ceva Santé Animale, Revival Animal Health Inc., Aromor Animal Health, Jorgensen Laboratories LLC, Pharmacosmos AS, Sykes Veterinary International Pty Ltd., Rusoma Laboratories Private Limited, Patterson Companies Inc., NexGen Veterinary, Soxa Formulations & Research Pvt. Ltd
Read the full veterinary intravenous (iv) solutions market report here:
Which Regions Are Expected To Experience Rapid Expansion In The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market?
North America was the largest region in the veterinary intravenous (IV) solutions market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veterinary intravenous (iv) solutions market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=20686&type=smp
Browse Through More Reports Similar to the Global Veterinary Intravenous (IV) Solutions Market 2026, By The Business Research Company
Veterinary Hematology Analyzers Global Market Report 2026
Veterinary Telehealth Market 2026
https://www.thebusinessresearchcompany.com/report/veterinary-telehealth-market
Veterinary Stereotactic Radiosurgery System Global Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
